Ongoing treatment(s)-Biological/Targeted therapy - Page 3 of 3 Posts on Medivizor
Navigation Menu

Ongoing treatment(s)-Biological/Targeted therapy Posts on Medivizor

Does G-B treatment improve survival outcomes for patients with refractory follicular lymphoma?

Does G-B treatment improve survival outcomes for patients with refractory follicular lymphoma?

Posted by on May 12, 2018 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study investigated the outcomes of patients with indolent (painless) refractory (does not respond to treatment) non-Hodgkin’s lymphoma (NHL) after G-B (obinutuzumab, bendamustine) treatment. This study concluded that G-B improved survival outcomes for NHL patients with similar side effects as bendamustine (Treanda)...

Read More

Looking for patients to test CAR T-cells in treating relapsed or refractory indolent non-Hodgkin lymphoma

Looking for patients to test CAR T-cells in treating relapsed or refractory indolent non-Hodgkin lymphoma

Posted by on Aug 29, 2017 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This phase 2 clinical trial will test the effectiveness of axicabtagene ciloleucel (KTE-C19) in treating relapsed or refractory (unresponsive to treatment) indolent non-Hodgkin’s lymphoma (iNHL). The primary outcome will be measured by the response rate.   The details Axicabtagene ciloleucel is a chimeric antigen...

Read More